RE: Health-related quality of life in patients with newly diagnosed advanced ovarian cancer receiving maintenance olaparib plus bevacizumab (PAOLA-1/ENGOT-ov25)

Health-related quality of life in patients with newly diagnosed advanced ovarian cancer receiving maintenance olaparib plus bevacizumab (PAOLA-1/ENGOT-ov25)

10.1093/jnci/djag122 · 2026

Health-related quality of life in patients with newly diagnosed advanced ovarian cancer treated with niraparib vs placebo: results from the phase 3 randomized PRIMA/ENGOT-OV26/GOG-3012 trial

10.1016/j.ygyno.2024.01.021 · 2024

International standards for the analysis of quality-of-life and patient-reported outcome endpoints in cancer randomised controlled trials: recommendations of the SISAQOL Consortium

10.1016/s1470-2045(19)30790-9 · 2020

Patient-centred outcomes and effect of disease progression on health status in patients with newly diagnosed advanced ovarian cancer and a BRCA mutation receiving maintenance olaparib or placebo (SOLO1): a randomised, phase 3 trial

10.1016/s1470-2045(21)00098-x · 2021

Impact of disease progression on health-related quality of life of advanced ovarian cancer patients—pooled analysis from the PRIMA trial

10.1016/j.ygyno.2022.06.028 · 2022

Evaluation of scores to reflect toxicity impact on quality of life of patients with platinum-resistant ovarian cancer: AURELIA substudy

10.6004/jnccn.2022.7101 · 2023